Eli Lilly stock surges after FDA approves obesity pill

Chronological Source Flow
Back

AI Fusion Summary

Eli Lilly's new obesity drug, orforglipron (Foundayo), has received FDA approval, positioning it to compete with Novo Nordisk's Wegovy. The approval came via the FDA's commissioner’s voucher program, expediting review for drugs addressing national health priorities.
01/04 18:36 investing.com
4 Πηγές
01/04 18:46 statnews.com
01/04 19:00 nbcnews.com
01/04 19:23 forbes.com
Comments
Loading...
0